

comments received will be provided to the Council.

**Public Disclosure of Comments:** Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

Detailed Council meeting minutes will be maintained in the Green River District Office and will be available for public inspection and reproduction during regular business hours within 90 days following each meeting. Minutes will also be posted to the Council web page.

**Authority:** 43 CFR 1784.4–2.

**Gregory Sheehan,**  
State Director.

[FR Doc. 2021–13112 Filed 6–22–21; 8:45 am]

**BILLING CODE 4310–DQ–P**

**JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES**

**Meeting of the Advisory Committee; Meeting**

**AGENCY:** Joint Board for the Enrollment of Actuaries.

**ACTION:** Notice of federal advisory committee meeting.

**SUMMARY:** The Joint Board for the Enrollment of Actuaries gives notice of a teleconference meeting of the Advisory Committee on Actuarial Examinations (a portion of which will be open to the public) on July 8 and 9, 2021.

**DATES:** Thursday, July 8, 2021, from 9:00 a.m. to 5:00 p.m. (EDT), and Friday, July 9, 2021, from 8:30 a.m. to 5:00 p.m. (EDT).

**ADDRESSES:** The meeting will be held by teleconference.

**FOR FURTHER INFORMATION CONTACT:** Ms. Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, at (202) 317–3648 or *Elizabeth.j.vanosten@irs.gov*.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet by teleconference on Thursday, July 8, 2021, from 9:00 a.m. to 5:00 p.m. (EDT), and Friday, July 9, 2021, from 8:30 a.m. to 5:00 p.m. (EDT).

The purpose of the meeting is to discuss topics and questions that may

be recommended for inclusion on future Joint Board examinations in actuarial mathematics and methodology referred to in 29 U.S.C. 1242(a)(1)(B) and to review the May 2021 Pension (EA–2L) and Basic (EA–1) Examinations in order to make recommendations relative thereto, including the minimum acceptable pass scores. Topics for inclusion on the syllabus for the Joint Board’s examination program for the November 2021 Pension (EA–2F) Examination will be discussed.

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the portions of the meeting dealing with the discussion of questions that may appear on the Joint Board’s examinations and the review of the May 2021 EA–2L and EA–1 Examinations fall within the exceptions to the open meeting requirement set forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such portions be closed to public participation.

The portion of the meeting dealing with the discussion of the other topics will commence at 1:00 p.m. (EDT) on July 8, 2021, and will continue for as long as necessary to complete the discussion, but not beyond 3:00 p.m. (EDT). Time permitting, after the close of this discussion by Committee members, interested persons may make statements germane to this subject. Persons wishing to make oral statements should contact the Designated Federal Officer at *NHQJBEA@IRS.GOV* and include the written text or outline of comments they propose to make orally. Such comments will be limited to 10 minutes in length. Persons who wish to attend the public session should contact the Designated Federal Officer at *NHQJBEA@IRS.GOV* to obtain teleconference access instructions. Notifications of intent to make an oral statement or to attend the meeting must be sent electronically to the Designated Federal Officer by no later than July 1, 2021. In addition, any interested person may file a written statement for consideration by the Joint Board and the Advisory Committee by sending it to *NQJBEA@IRS.GOV*.

Dated: June 17, 2021.

**Thomas V. Curtin, Jr.,**  
Executive Director, Joint Board for the Enrollment of Actuaries.

[FR Doc. 2021–13174 Filed 6–22–21; 8:45 am]

**BILLING CODE 4830–01–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–856]

**Bulk Manufacturer of Controlled Substances Application: Purisys, LLC.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Purisys, LLC. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2021. Such persons may also file a written request for a hearing on the application on or before August 23, 2021.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March, 12, 2021, Purisys, LLC., 1550 Olympic Drive, Athens, Georgia 30601–1602, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

| Controlled substance                   | Drug code | Schedule |
|--|-----------|----------|
| 3,4-Methylenedioxyamphet-amine.        | 7400      | I        |
| 3,4-Methylenedioxymetha-mphetamine.    | 7404      | I        |
| 3,4-Methylenedioxy-N-ethylamphetamine. | 7405      | I        |
| Psilocybin .....                       | 7437      | I        |
| Psilocyn .....                         | 7438      | I        |

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. The company plans to manufacture the above-listed controlled substances as clinical trial and starting materials to make compounds for distribution to its customers. No other